Paper82030
Levamisole in rheumatoid arthritis. A randomised double-blind study comparing two dosage regimens of levamisole with placebo. Multicentre study group.
Lancet, 1978. Cited by 14 papers, by iCite.
Cite this record
ConductScience Library. Levamisole in rheumatoid arthritis. A randomised double-blind study comparing two dosage regimens of levamisole with placebo. Multicentre study group. Papers, record 82030. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/82030
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Arthritis, Rheumatoid | Major topic |
| Levamisole | Major topic |
| Administration, Oral | |
| Adolescent | |
| Adult | |
| Aged | |
| Clinical Trials as Topic | |
| Drug Evaluation | |
| Female | |
| Humans | |
| International Cooperation | |
| Middle Aged | |
| Placebos | |
| Research Design | |
| Time Factors |
Source PubMed
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 14 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39598415 | Levamisole Ameliorates Rheumatoid Arthritis by Downregulating the PI3K/Akt Pathway in SD Rats. | Pharmaceuticals (Basel) | 2024 | https://conductscience.org/library/papers/39598415 | PubMed |
| 37801318 | Monotreatment With Conventional Antirheumatic Drugs or Glucocorticoids in Rheumatoid Arthritis: A Network Meta-Analysis. | JAMA Netw Open | 2023 | https://conductscience.org/library/papers/37801318 | PubMed |
| 7166176 | Pharmacokinetics of levamisole in healthy subjects and cancer patients. | Eur J Drug Metab Pharmacokinet | 1982 | https://conductscience.org/library/papers/7166176 | PubMed |
| 7144065 | [Granulocytotoxic antibodies in levamisole-induced agranulocytosis]. | Klin Wochenschr | 1982 | https://conductscience.org/library/papers/7144065 | PubMed |
| 7009134 | Antirheumatic drugs: clinical pharmacology and therapeutic use. | Drugs | 1980 | https://conductscience.org/library/papers/7009134 | PubMed |
| 6967398 | An overview of the current status of levamisole in the treatment of rheumatic diseases. | Drugs | 1980 | https://conductscience.org/library/papers/6967398 | PubMed |
| 6432411 | An European open multicentre trial with auranofin in rheumatoid arthritis. | Clin Rheumatol | 1984 | https://conductscience.org/library/papers/6432411 | PubMed |
| 3056695 | The optimum management of arthropathies. | Drugs | 1988 | https://conductscience.org/library/papers/3056695 | PubMed |
| 3055380 | New approaches to the treatment of rheumatoid arthritis. | Springer Semin Immunopathol | 1988 | https://conductscience.org/library/papers/3055380 | PubMed |
| 2785367 | Reflection of disease activity in rheumatoid arthritis by indices of activation of the classical complement pathway. | Ann Rheum Dis | 1989 | https://conductscience.org/library/papers/2785367 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Authors
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/82030
GET https://conductscience.org/api/papers/v1/82030/authors